BACKGROUNDThe emerging role of vitamin D in immunology and autoimmune disorders has been a worldwide interest in the last decade. Systemic lupus erythematosus (SLE) patients are particularly at a delicate position predisposing them to suffer from vitamin D deficiency due to the multiple risk factors accompanying the disease. Whether vitamin D deficiency is also involved as a risk factor for developing SLE and affecting its course is a considerable concern.OBJECTIVESThe objective of this study was to estimate the prevalence of vitamin D deficiency in SLE patients and its relation to disease.MATERIALS AND METHODSIn our observational cross-sectional study, serum levels of vitamin D [25(OH)D] in 60 SLE patients and 30 age- and sex-matched healthy controls were assessed and estimated for deficiency and insufficiency at 10 and 30 ng/mL, respectively. Disease activity was evaluated by SLE disease activity index (SLEDAI), irreversible organ damage by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI), and severity by Severity of Disease Index. Fatigue was measured by visual analog scale.RESULTSSignificantly lower levels of 25(OH)D were found in SLE patients (17.6 ± 6.9 ng/mL) in comparison to controls (79.0 ± 28.7 ng/mL), with a statistically high significant difference (t = −11.2, P < 0.001). High prevalence of vitamin D insufficiency and deficiency was detected as 73.3% and 23.3%, respectively. Vitamin D had a highly significant negative correlation with SLEDAI (r = −0.495, P < 0.001), SLICC (r = −0.431, P < 0.05), and fatigue (r = −0.436, P < 0.05).CONCLUSIONVitamin D deficiency and insufficiency were found to be prevalent in SLE patients in our study and related to disease activity and fatigue. If needed, routine screening and consequent repletion of vitamin D are recommended in SLE patients. Restoring adequate vitamin D levels in SLE patients should be more explored as a potential yet simple measure to their usual management to improve their condition.

No abstract

Introduction: Sickle cell disease (SCD) is a genetic disorder with autosomal recessive inheritance causing abnormal hemoglobin. It is an important medical problem globally as well as in our community at Eastern province of Saudi Arabia. It accounts for large numbers of morbidity and to a lesser extent mortality. Several natural plant products over the world, which were known in some communities and their traditional healers, were studied and found to have properties in improving SCD manifestation. This research was planned to explore if any plant product under our study could prove being an effective anti-sickling agent for therapeutic use in SCD management. Objectives: Studying the effects of some plants on sickled RBCs as well as comparing between efficacies of these different plants. Material and Methods: The 49 fresh whole blood samples, extracted through venipuncture in EDTA tubes, were collected from known SCD patients whose homozygosity were confirmed by hemoglobin electrophoresis. These patients were not on recent blood transfusion or hydroxyurea, and aged 14 years or above of both sexes on clinical follow up. The dried rhizomes of turmeric (curcuma longa) powder and dried seeds flour of fenugreek (trigonella foenum-graecum) were used to evaluate the reversal type of anti-sickling activity on RBCs. Results: Out of 49 blood samples, 28 (57.1%) samples were from males and 21 (42.9%) samples from females. The average (±SD) age of the cases was 28.2 (±9.97) years with range 14 – 60 years. Significant anti-sickling activity was found using Turmeric rhizomes extract treatment with 66.81% reversal effect, and 61.28% anti-sickling action when fenugreek seeds extract was used. Conclusion: The findings of this study suggest that turmeric (C. longa) rhizome extract and fenugreek seed extract could have promising anti-sickling properties for SCD treatment.